Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Incyte Corporation
Study ID
NCT07218744
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
MALE
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • INCB123667 — DRUG
    INCB123667 will be administered orally as a tablet dose, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB123667.

Study Details

This study will assess the mass balance, pharmacokinetics, and metabolite profiles of a single oral dose of \[14C\] INCB123667 in healthy male participants.

Key Dates

Start date
Nov 13, 2025
Status verified
Jan 2026
Primary completion
Dec 10, 2025
Completion
Dec 10, 2025

Study Design

Enrollment
9 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment: INCB123667
    Participants will be administered INCB123667 tablet orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB123667.

Primary Outcome Measure

Total Recovery (Urine + Feces) of the Administered Radioactivity [ Time Frame: Approximately 2 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research Unit Ltd Labcorp Clinical Research Unit Limited MadisonMadisonWisconsin53704-

Find similar trials in Madison, WI

By research site
Fortrea Clinical Research Unit Ltd Labcorp Clinical Research Unit Limited Madison· Madison, WI

Related Studies